ARS Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

ARS Pharmaceuticals (Nasdaq: SPRY) will participate in the Piper Sandler 37th Annual Healthcare Conference in New York, December 2-4, 2025.

Company executives Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer, will take part in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Management will hold one-on-one investor meetings. A live webcast of the fireside chat will be available on the company website and a replay will be archived for 90 days.

SAN DIEGO, Nov. 26, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced its participation at the Piper Sandler 37^th Annual Healthcare Conference, December 2-4, 2025, in New York.

Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in a fireside chat on Wednesday, December 3 at 2:30 pm ET with Piper Sandler analyst David Amsellem. Company management will also participate in one-on-one meetings with investors.

A live webcast of the fireside chat will be available here, and in the Investors & Media section of the Company’s website. A replay of the webcast will be archived on the Company’s website for 90 days.

About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.

Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com

Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
615.414.8668

FAQ

When will ARS Pharmaceuticals (SPRY) present at the Piper Sandler 37th Annual Healthcare Conference?

ARS will participate December 2-4, 2025, with a fireside chat on December 3, 2025 at 2:30 pm ET.

Who from ARS Pharmaceuticals (SPRY) will speak at the Piper Sandler conference?

Richard Lowenthal, Co-Founder, President and CEO, and Eric Karas, Chief Commercial Officer.

How can investors watch ARS Pharmaceuticals' (SPRY) fireside chat on December 3, 2025?

A live webcast will be available on the company's Investors & Media website, with a replay archived for 90 days.

Will ARS Pharmaceuticals (SPRY) hold meetings with investors at the conference?

Yes, company management will participate in one-on-one investor meetings during the conference.

Where will the ARS Pharmaceuticals (SPRY) webcast replay be accessible and for how long?

The replay will be archived in the Investors & Media section of the company website for 90 days.

What time is the ARS Pharmaceuticals (SPRY) fireside chat with Piper Sandler on December 3, 2025?

The fireside chat is scheduled for 2:30 pm ET on Wednesday, December 3, 2025.